Brilinta’s patent nullification competition fueled even more among pharmaceutical companies

While domestic pharmaceutical companies are competing over the patent nullification of the AstraZeneca’s antithrombotic, ‘Brilinta,’ the recent establishment of many claims for the patent is expected to solidify the competition.

Recently, the Intellectual Property Tribunal ruled establishment of claims on the 1^st at the defensive confirmation trial for the scope of the patent(composition suita...